{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-059717","form_type":"8-K","ticker":"IDYA","cik":"0001676725","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.031616+00:00","generated_at":"2026-06-08T16:02:06.334396+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"IDEAYA Q3 cash $511M, darovasertib shows 42% ORR in 1L HLA-A2(-) MUM; registrational trial ongoing","bullets":["Cash, cash equivalents and marketable securities of $511.1M as of Sep 30, 2023; plus $134.7M net proceeds from follow-on and $10M GSK milestone receivable.","Darovasertib + crizotinib in 1L HLA-A2(-) MUM: ORR 42%, median PFS 7.1 months; Phase 2/3 registrational trial ongoing with >50 sites planned.","Darovasertib neoadjuvant in primary UM: 50% eye preservation rate (3/6 evaluable), tumor shrinkage in 83% of evaluable patients.","IDE161 received FDA Fast Track for BRCA1/2 ovarian and breast cancer; Phase 1 expansion initiated in HRD+ tumors.","IND clearance for GSK101 (Pol Theta) triggered $7M milestone; Werner Helicase DC selected with $3M milestone; IND targeted in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-059717","json":"https://secwatch.observer/filing/0000950170-23-059717.json","markdown":"https://secwatch.observer/filing/0000950170-23-059717.md","text":"https://secwatch.observer/filing/0000950170-23-059717.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000095017023059717/0000950170-23-059717-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000095017023059717/idya-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T16:02:06.334396+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4d401f8747b2ee6c6dae17791e110657cf21ca85","claim":"IDEAYA Biosciences, Inc. reported financial results for third quarter ended September 30, 2023.","evidence_excerpt":"announced its financial results for the third quarter ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1676725/000095017023059717/0000950170-23-059717-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}